Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Saxagliptin VS. Glimepiride in Chinese T2DM Patients Controlled Inadequately With Metformin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* For inclusion in the study subjects should fulfill the following criteria:~* Provision of informed consent prior to any study specific procedures~* Type2 diabetic patients had been on stable, maximum tolerated doses of metformin (≧1500mg/d, ≧8 weeks)~* Male or female age ≧ 25 years and ≦75 years old~* HbA1c ≧7.0 and ≦9.5%~* BMI ≧ 20 and ≦ 30 kg/m2~Exclusion Criteria:~* Subjects should not enter the study if any of the following exclusion criteria are fulfilled:~* Known or suspected allergy to trial products or related products.~* Impaired renal function defined as serum-creatinine ≥ 1.5 mg/dL (≥ 132.6 μmol/l).~* Acute or chronic disease which may cause tissue hypoxia such as cardiac or respiratory failure, shock.~* Hepatic insufficiency, acute alcohol intoxication, alcoholism.~* Subjects has a clinically significant, active (or over the past 12 months) cardiovascular history (including a history of myocardial infarction (MI), arrhythmias or conduction delays on ECG, unstable angina, or decompensated heart failure (New York Heart Association-class Ⅲ and Ⅳ).~* Proliferative retinopathy or muscular oedema requiring acute treatment.~* Lactation.~* Pregnant or positive pregnancy test at screening, nursing mother, or unwillingness to use adequate contraception (adequate contraceptive measures are sterilization, intrauterine device, oral contraceptives or barrier methods).~* Treatment with systemic corticosteroids within the past two months prior to screening.~* Tested positive for glutamic acid decarboxylase antibody.~* Receipt of any investigational drug within 1 month prior to this trial.

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Saxagliptin (Type: ACTIVE_COMPARATOR): The treatment of saxagliptin will be initiated and maintained at 5mg every morning until the completion of the test.Meanwhile,subjects will be instructed to take stable doses of metformin (1500mg/d) through the whole trial.
- Glimepiride (Type: ACTIVE_COMPARATOR): Glimepiride will be initially treated with 1 mg every morning to a dose of 6 mg/day.a.m. Every 4-week the subjects will be evaluated whether reach the target fasting plasma glucose (assayed by finger-stick ≦6.1 mmol/l ). If the fasting blood glucose not achieved the target at the maximum dose, maintain the maximum dose(6mg/d) until the completion of the test.Meanwhile,subjects will be instructed to take stable doses of metformin (1500mg/d) through the whole trial.

Based on this trial design, predict the completion outcome and termination type (if applicable).